CRIZANLIZUMAB is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.[1]


Pathophysiology

P-selectin molecules are present on the surface of vascular endothelial cells and have been linked to Sickle cell vaso-occlusive crises.[2]


References

Category:Hematology Category:Sickle-cell disease Category:Monoclonal antibodies Category:Breakthrough therapy

[1]

[2]